Thursday, June 25, 2026
🇺🇸 FDA

Regulatory Tools - Pipeline Valuation

rNPV Calculator

Estimate risk-adjusted net present value for pharmaceutical and biotech assets using cumulative probability of success by clinical phase, peak revenue assumptions, exclusivity timing, and WACC. Educational triage only—not investment advice.

Quick Answer

Risk-adjusted NPV (rNPV) values pharmaceutical pipeline assets by multiplying projected commercial cash flows by cumulative probability of success (PoS) from the current clinical phase, then discounting at WACC. This free calculator uses BIO-style phase PoS presets and peak-revenue assumptions — the same core logic as gated BD platforms like PhaseFolio, without login or paywall. For triage and education only, not final deal pricing.

rNPV Formula

Core equation

rNPV = Σ [ CF_t × PoS / (1 + r)^t ]

Variables

CF = annual revenue ($M), PoS = cumulative LoA from current phase, r = WACC, t = year from today

Versus NPV

NPV sets PoS = 100%; rNPV applies phase-appropriate success probability to each cash flow

Risk-Adjusted NPV Estimator

Model probability-weighted commercial revenue from today. Development costs, milestones, and tax are not included in this simplified Wave A version.

Development stage

Cumulative LoA from this phase: 7.9% (BIO industry average).

Commercial assumptions

Global peak annual sales or revenue proxy in millions of US dollars.

Linear ramp from launch to peak revenue.

Years at peak revenue before modeled revenue stops (LOE cliff).

Discount rate after PoS adjustment; typically 8–12% for rNPV models.

Years until first commercial revenue; includes remaining development and filing time you expect.

Risk-adjusted NPV

-

-

Unadjusted NPV (PoS = 100%) -
Cumulative PoS applied -
Modeled revenue years -
Peak revenue input -

-

Worked Example

A Phase 2 oncology asset with $800M peak sales, five years to peak, eight exclusivity years at peak, four years until launch, and 10% WACC illustrates how PoS compresses value versus raw NPV.

Input Value Notes
Phase Phase 2 Cumulative LoA ≈ 20.9% (BIO industry average)
Peak revenue $800M / year Global peak sales proxy
Years to peak 5 Linear ramp from launch (year 5) through year 9
Exclusivity at peak 8 years Flat peak from year 9 through year 16
Launch delay 4 years No revenue in years 1–4
WACC 10% PoS already captures clinical risk

Click Load Example in the calculator to populate these values. The tool discounts the ramp-and-plateau revenue stream, then multiplies by 20.9% PoS. rNPV is materially lower than unadjusted NPV because most Phase 2 programs never reach approval.

Probability of Success Reference (BIO Industry Averages)

Cumulative likelihood of approval (LoA) from the current phase uses rounded BIO Clinical Development Success Rates and related industry summaries. Oncology, rare disease, and modality-specific PoS can differ sharply—replace these defaults for deal-grade work.

Current phase Phase transition (approx.) Cumulative LoA to approval
Preclinical → Phase 1 ~60% 7.9%
Phase 1 → Phase 2 ~63% 13.8%
Phase 2 → Phase 3 ~31% 20.9%
Phase 3 → Approval ~58% 53.4%
Filed / NDA or BLA → Approval ~91% 90.6%

rNPV vs NPV in Pharma Valuation

Standard NPV / high hurdle DCF Often assumes success and uses 30–60%+ discount rates for early biotech. Risk is embedded in the rate, which can double-count uncertainty when paired with conservative sales forecasts.
rNPV / expected NPV Separates clinical risk (PoS weights) from financial discounting (WACC). Preferred for licensing, M&A triage, and portfolio ranking when cash flows can be structured by phase gate.
Professional platforms PhaseFolio, BioHeights, Ambrosia Ventures, and Tamal Adebisi-style models add indication-specific PoS, cost lines, Monte Carlo ranges, and deal comps. This page teaches the core math without proprietary datasets.

Sources and Methodology Notes

Probability benchmarks align with BIO industry summaries of clinical development success rates and widely cited transition probabilities (Preclinical→Phase 1 ~60%, Phase 1→2 ~63%, Phase 2→3 ~31%, Phase 3→approval ~58%, NDA→approval ~91%). WIPO guidance on biotech IP valuation describes rNPV as probability-weighted DCF with cost of capital separate from technical success probability. Analysis Group and healthcare investment banking primers discuss avoiding double-counting of risk when PoS is applied.

This calculator does not reproduce proprietary PoS tables from PhaseFolio, BioHeights, or Ambrosia. For FDA action timing linked to valuation, pair results with the PDUFA Date Calculator and exclusivity or patent tools below.

Evidence & sources

Frequently Asked Questions

Risk-adjusted net present value (rNPV) is a probability-weighted discounted cash flow method used to value drug development assets. Each projected cash flow is multiplied by the cumulative probability that the program reaches that stage, then discounted to present value at a cost-of-capital rate such as WACC.
Standard NPV assumes all projected cash flows occur with certainty and often uses a high hurdle rate to embed risk. rNPV separates clinical and regulatory risk into explicit probability-of-success (PoS) weights and typically uses a lower discount rate (often 8–12% WACC) so development risk is not double-counted.
Industry benchmarks vary by therapeutic area, modality, and biomarker strategy. This calculator uses BIO-style cumulative likelihood-of-approval (LoA) averages from the current phase: Preclinical ~7.9%, Phase 1 ~13.8%, Phase 2 ~20.9%, Phase 3 ~53.4%, and Filed/NDA ~90.6%. Replace with indication-specific PoS for deal work.
Because PoS already captures clinical attrition, most rNPV models use WACC in the 8–12% range rather than 40%+ hurdle rates. Large-cap pharma often sits near 8–9%, mid-cap biotech near 10–11%, and early-stage or pre-revenue companies toward 11–12%, adjusted for capital structure and systematic risk.
No. This Wave A tool models probability-weighted commercial revenue only—a simplified income-side rNPV. Full licensing or M&A models also probability-weight remaining development costs, milestones, royalties, tax, and terminal value. Use this output for triage and education, not final deal pricing.
Launch delay pushes revenue farther into the future, reducing present value through discounting. If exclusivity is measured from launch, delay can also shorten the effective peak-revenue window before loss of exclusivity unless the model extends the commercial period separately.
PhaseFolio, BioHeights, Ambrosia Ventures, and similar platforms add indication-specific PoS, Monte Carlo simulation, cost lines, and deal comparables. This free calculator follows the same core rNPV logic—PoS-weighted cash flows discounted at WACC—for quick pipeline triage and learning.
Cumulative PoS from the current phase reflects the joint probability of passing remaining clinical trials and obtaining regulatory approval. Weighting future revenue by that probability converts an optimistic NPV into an expected-value estimate appropriate for early-stage assets.
Revenue ramps linearly from zero to peak over the years-to-peak input, stays at peak for the exclusivity-years input after peak is reached, then stops. There is no post-LOE tail, country rollout detail, or price erosion unless you adjust inputs manually.
Yes. rNPV, expected NPV, probability-weighted NPV, and PTRS-adjusted DCF are closely related income-approach methods described in WIPO biotech valuation guidance and healthcare investment banking practice. Terminology differs by firm, but the core PoS × discounted cash flow structure is the same.
rNPV is preferred when enough clinical and commercial assumptions exist to forecast cash flows. Venture-capital or milestone-multiple methods appear more often at seed stage or when data are sparse. Many business-development teams run rNPV alongside real-options or VC cross-checks.
Yes. A negative rNPV means probability-weighted commercial cash flows, at the chosen WACC, do not justify the asset value implied by the inputs—often before subtracting remaining development spend. Negative rNPV does not automatically mean stop development; strategic, portfolio, or platform value may still apply.

Related Regulatory Tools

PDUFA Date Calculator Patent Expiry Calculator Exclusivity Period Calculator

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.